In CML, expression of Irf8 increases with remission, decreases with relapse, and is lowest during progression to myeloid blast crisis (BC or acute myeloid leukemia [AML]) (13). Here, IRF8 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.